A Phase Ib Study of Lucitanib (AL3810) in a Cohort of Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma

BACKGROUND: Lucitanib is a novel multi-target inhibitor of FGFR1-3, VEGFR 1-3, and PDGFR α/β. Here, we evaluated the safety, tolerability, and preliminary efficacy of lucitanib in recurrent and metastatic nasopharyngeal carcinoma (RM-NPC). METHODS: Patients with pretreated RM-NPC were randomly divid...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yang, Luo, Fan, Ma, Yu-Xiang, Liu, Qian-Wen, Yang, Yun-Peng, Fang, Wen-Feng, Huang, Yan, Zhou, Ting, Li, Jin, Pan, Hong-Ming, Yang, Lei, Qin, Shu-Kui, Zhao, Hong-Yun, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177108/
https://www.ncbi.nlm.nih.gov/pubmed/35445718
http://dx.doi.org/10.1093/oncolo/oyab076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177108/
https://www.ncbi.nlm.nih.gov/pubmed/35445718
http://dx.doi.org/10.1093/oncolo/oyab076

Ejemplares similares